Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Travoprost/Timolol vs Latanoprost/Timolol in Chinese Patients with Glaucoma or Ocular Hypertension
NCT00872651Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jan 2010
- Primary completion
- Nov 2011
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of travoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Alcon Inc. Primary endpoint: Mean Diurnal Intraocular Pressure Change from Baseline at 8 weeks. Started Jan 2010; status: completed.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00872651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00872651.